MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

Search

Harvard Bioscience Inc

Ouvert

SecteurSoins de santé

0.6 3.45

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.56

Max

0.61

Chiffres clés

By Trading Economics

Revenu

1.1M

-1.2M

Ventes

141K

21M

Marge bénéficiaire

-5.978

Employés

330

EBITDA

1M

1.2M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+244.83% upside

Dividendes

By Dow Jones

Prochains Résultats

11 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

616K

26M

Ouverture précédente

-2.85

Clôture précédente

0.6

Sentiment de l'Actualité

By Acuity

26%

74%

71 / 360 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Harvard Bioscience Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 janv. 2026, 23:49 UTC

Principaux Mouvements du Marché

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 janv. 2026, 21:12 UTC

Principaux Mouvements du Marché

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 janv. 2026, 21:00 UTC

Acquisitions, Fusions, Rachats

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 janv. 2026, 20:29 UTC

Principaux Mouvements du Marché

Chip Makers Gain After Trump Calls Off European Tariffs

21 janv. 2026, 20:04 UTC

Principaux Mouvements du Marché

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 janv. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 janv. 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 janv. 2026, 22:39 UTC

Résultats

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 janv. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 janv. 2026, 21:35 UTC

Acquisitions, Fusions, Rachats

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 janv. 2026, 21:19 UTC

Résultats

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 janv. 2026, 20:45 UTC

Acquisitions, Fusions, Rachats

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 janv. 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 janv. 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 janv. 2026, 20:27 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 janv. 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 janv. 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21 janv. 2026, 20:26 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 janv. 2026, 20:23 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 janv. 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 janv. 2026, 20:19 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse Group Agrees to Buy Allfunds

21 janv. 2026, 20:08 UTC

Résultats

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 janv. 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 janv. 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 janv. 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21 janv. 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21 janv. 2026, 19:24 UTC

Résultats

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 janv. 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 janv. 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Comparaison

Variation de prix

Harvard Bioscience Inc prévision

Objectif de Prix

By TipRanks

244.83% hausse

Prévisions sur 12 Mois

Moyen 2 USD  244.83%

Haut 2 USD

Bas 2 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.3 / 0.3401Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

No Evidence

Long Terme

No Evidence

Sentiment

By Acuity

71 / 360Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat